GUFICBIO vs LINCOLN: Stock Comparison
GUFIC BIOSCIENCES is the larger company by market capitalisation. GUFIC BIOSCIENCES shows faster revenue growth, while LINCOLN PHARMA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GUFICBIO leads 2; LINCOLN leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| Live Price | ₹394 | ₹510.85 |
| Day Change | 1.16% | -0.72% |
| Volume | 1.11 L | 61,149 |
| 52-Week High | ₹467.8 | ₹770 |
| 52-Week Low | ₹268 | ₹440 |
| Distance from 52W High | -15.78% | -33.66% |
Valuation
| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| Market Cap | ₹3,948 Cr | ₹1,023 Cr |
| P/E Ratio | 53.78x | 10.61x |
| P/B Ratio | 5.94x | 1.35x |
| EPS | ₹2.22 | ₹18.09 |
| Book Value | ₹66.31 | ₹378.25 |
| Dividend Yield | 0.03% | 0.35% |
Growth
| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.8% | 11.4% |
| EPS Growth (TTM YoY) | 183.1% | 0.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| ROE | 9.66% | 11.6% |
| ROCE | 9.25% | 10.97% |
| Net Margin | 6.8% | 13.1% |
| Operating Margin | 13.05% | 17.38% |
| Debt to Equity | 0.58x | 0.01x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | GUFICBIO | LINCOLN |
|---|---|---|
| Promoter Holding | 72.5% | 49.78% |
| FII Holding | 0.45%▼ 0.01 pp | 4.6%▼ 0.59 pp |
| DII Holding | 3.38%▼ 0.3 pp | 0.27%▼ 0.82 pp |
| Public Holding | 23.67%▲ 0.31 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GUFIC BIOSCIENCES and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.